Merck & Co., Inc. is 188.5x more valuable than Sarepta Therapeutics, Inc. by market capitalization ($298.26 B vs $1.58 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | SRPT | MRK |
|---|---|---|
| Market cap | $1.58 B | $298.26 B |
| US-listed rank | #2292 | #45 |
| Revenue (latest FY) | $2.20B | $65.01B |
| Net income (latest FY) | -$713.41M | $18.25B |
| Net margin | -32.5% | 28.1% |
| P/E (trailing FY) | - | 16.3 |
| SEC filings | 1,504 | 996 |
Merck & Co., Inc. is 188.5x more valuable than Sarepta Therapeutics, Inc. by market capitalization ($298.26 B vs $1.58 B).
In their latest fiscal years, Sarepta Therapeutics, Inc. reported $2.20B in revenue while Merck & Co., Inc. reported $65.01B.
Full pages: Sarepta Therapeutics, Inc. and Merck & Co., Inc., or browse the full rankings.